The U.S. Food and Drug Administration (FDA has cleared the investigational new drug (IND) application for Allogene Therapeutics’ ALLO-329, an investigational allogenic CAR-T cell therapy.

A new study found that low or absent disease activity, hydroxychloroquine (HCQ) use, and gradual reduction of GC dosing can ...

Exagen Inc. has announced conditional approval from the New York State Department of Health for its innovative new biomarker ...

The way we talk about lupus – to ourselves and with others – matters. Living with lupus can feel like a daily battle filled with uncertainty. Negative self-talk about this disease and its limitations ...

The Phase 1 GALLOP study evaluating the investigational therapy, CB-010, for treatment of lupus nephritis has launched.

Explore our lupus resources in English, Spanish, and Chinese. The Lupus Foundation of America, as Secretariat of the World Lupus Federation (WLF), provides various resources for WLF member ...

If your child has lupus, this template letter can help you schedule a meeting with the school to educate their teachers and counselors about lupus and discuss a plan so your child can stay healthy and ...

This episode of The Expert Series explores the complex relationship between lupus and fibromyalgia, focusing on definitions, symptoms, overlapping conditions, treatment approaches, mental health ...

Neutropenia, a condition characterized by low neutrophil levels, is common in individuals with systemic lupus erythematosus (SLE) and can lead to severe infections. A new study investigates the role ...

An investigator-initiated Phase 1/2 trial of CNTY-101, an investigational therapy, has been announced for the treatment of B-cell mediated autoimmune diseases, including systemic lupus erythematosus ...

Serving north, central and west Texas, including Dallas/Fort Worth, San Antonio, Austin, El Paso, Lubbock, and surrounding areas Join us for the 2025 Portland Lupus & You Empowerment Conference! Lupus ...